Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, Neuberger JM, Day DB, Ducker SJ; UK PBC Consortium, Sandford RN, Alexander GJ, Jones DE.

Gastroenterology. 2013 Mar;144(3):560-569.e7; quiz e13-4. doi: 10.1053/j.gastro.2012.12.005. Epub 2012 Dec 12.

PMID:
23246637
3.

The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up.

Jones DE, Al-Rifai A, Frith J, Patanwala I, Newton JL.

J Hepatol. 2010 Nov;53(5):911-7. doi: 10.1016/j.jhep.2010.05.026. Epub 2010 Aug 1.

PMID:
20800924
4.

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.

Papastergiou V, Tsochatzis EA, Rodriguez-Peralvarez M, Thalassinos E, Pieri G, Manousou P, Germani G, Rigamonti C, Arvaniti V, Karatapanis S, Burroughs AK.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1354-64. doi: 10.1111/apt.12522. Epub 2013 Oct 5. Erratum in: Aliment Pharmacol Ther. 2014 Apr;39(8):904. Rodriquez-Peralvarez, M [corrected to Rodriguez-Peralvarez, M].

5.

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group.

Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.

PMID:
19208346
6.

Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.

Ozaslan E, Efe C, Heurgué-Berlot A, Kav T, Masi C, Purnak T, Muratori L, Ustündag Y, Bresson-Hadni S, Thiéfin G, Schiano TD, Wahlin S, Muratori P.

Clin Gastroenterol Hepatol. 2014 May;12(5):863-9. doi: 10.1016/j.cgh.2013.09.021. Epub 2013 Sep 26.

PMID:
24076417
7.

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.

Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH.

Liver Transpl. 2007 Sep;13(9):1236-45.

8.

Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.

Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxì A.

Aliment Pharmacol Ther. 2000 Dec;14(12):1645-52.

9.

The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

Pells G, Mells GF, Carbone M, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ; UK-PBC Consortium, Sandford RN, Alexander GJ, Jones DE.

J Hepatol. 2013 Jul;59(1):67-73. doi: 10.1016/j.jhep.2013.02.019. Epub 2013 Mar 4.

PMID:
23466308
10.

Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis.

Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, Onji M.

J Gastroenterol. 2009;44(6):630-4. doi: 10.1007/s00535-009-0051-9. Epub 2009 Apr 16.

PMID:
19370305
11.

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.

Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR.

Aliment Pharmacol Ther. 1998 Oct;12(10):965-71.

12.

[A two-year follow-up study on the efficacy of ursodeoxycholic acid on primary biliary cirrhosis in different stages].

Zhu JY, Li ZS, Yan W, Wang JH, Zhou XM, Wang RA, Huang XF, Shi YQ, Dong XY, Han ZY, Han Y.

Zhonghua Gan Zang Bing Za Zhi. 2010 Oct;18(10):735-9. doi: 10.3760/cma.j.issn.1007-3418.2010.10.004. Chinese.

PMID:
21059288
13.

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid.

Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, Dickson ER.

Liver. 1999 Apr;19(2):115-21.

PMID:
10220741
14.

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.

van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW.

J Hepatol. 1999 Aug;31(2):256-62.

PMID:
10453938
15.

Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease.

Heurgué A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, Louvet H, Frémond L, Geoffroy P, Schmit JL, Cadiot G, Thiéfin G.

Gastroenterol Clin Biol. 2007 Jan;31(1):17-25.

16.

Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.

Trivedi PJ, Bruns T, Cheung A, Li KK, Kittler C, Kumagi T, Shah H, Corbett C, Al-Harthy N, Acarsu U, Coltescu C, Tripathi D, Stallmach A, Neuberger J, Janssen HL, Hirschfield GM.

J Hepatol. 2014 Jun;60(6):1249-58. doi: 10.1016/j.jhep.2014.01.029. Epub 2014 Feb 15.

PMID:
24548531
17.

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R.

Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.

PMID:
18752324
18.

Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.

Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Homburger HA, Dickson ER, Krom RA, Wiesner RH, Lindor KD.

Hepatology. 1997 Jul;26(1):22-6.

PMID:
9214447
19.

Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.

Heathcote EJ, Stone J, Cauch-Dudek K, Poupon R, Chazouilleres O, Lindor KD, Petz J, Dickson ER, Poupon RE.

Liver Transpl Surg. 1999 Jul;5(4):269-74.

20.

Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.

Guo GY, Shi YQ, Wang L, Ren X, Han ZY, Guo CC, Cui LN, Wang JB, Zhu J, Wang N, Zhang J, Cai Y, Han Y, Zhou XM, Fan DM.

Aliment Pharmacol Ther. 2015 Jul;42(2):221-30. doi: 10.1111/apt.13244. Epub 2015 May 18.

PMID:
25982180
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk